Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pitch Deck for The Big Bang Competition Round 2

Similar presentations


Presentation on theme: "Pitch Deck for The Big Bang Competition Round 2"— Presentation transcript:

1 Pitch Deck for The Big Bang Competition Round 2
Benjamin Wang MD 2/19/2015

2

3

4 Improving Lives one Bottle at a Time
Non-Profit Founded in 2014 Scalable, Self-sustaining Recycling solution to: Address Homelessness Create paid volunteer opportunities Provide affordable green housing Hand up for education/training

5 Purpose of Round 2 Content: Much more than an investor pitch deck
Still needs to work in 17 seconds Lead with your stronger slides Content: Much more than an investor pitch deck Must Make Sense Simple Wording Don’t read off your slides Don’t bad mouth your competition

6 Pitching and Jokes Personal elements draw the audience into the story
Metaphor, Similes, Secrets, You Make the audience feel smart Give them a glimpse of what is coming up, tell them a story Surprise them Give them a something good to chew on Show them that you can bootstrap it Everything easy has been done We did that and here are the results What else can be done without funding

7 Judging Criteria Clarity (How it will make $) 1 pt- Unclear Summary
3 pt- Close but needs work 5 pt- Very Clear Viability (How likely it will make $) 1 pt- Little shown viability 3 pt- Close but needs work 5 pt- Strong Viability

8 Life and Healthcare Saving Innovations
Benjamin R. Wang MD CMO/Founder

9 Nevap Overview Medical Device to prevent US Patent Filed (Oct 2013) 3rd Generation Prototype Team Assembled Ventilator Associated Pneumonia (VAP) US Billion problem

10 Team Janet Kowalyski Harold Carrison Sandra Forrer Benjamin Wang MD
Brenton Hanlon Regulatory Engineering Quality Assurance Founder/CMO CEO

11 Problematic Gold Standard: SSET tube
50,000 US cases each year 300,000 US at risk/yr Avr Treatment cost $40K Source: Center of Disease Control & Prevention 11

12 Problematic Gold Standard: SSET tube
50,000 US cases each year 300,000 US at risk/yr Avr Treatment cost $40K No Medicare reimbursement Growing Global ICU needs Source: Center of Disease Control & Prevention 12

13 Problematic Gold Standard: SSET tube
50,000 US cases each year 300,000 US at risk/yr Avr Treatment cost $40K No Medicare reimbursement Growing Global ICU needs Era of Multi-antibiotic resistance “Superbugs” Source: Center of Disease Control & Prevention 13

14 Ventilator Associated Pneumonia
Source: Medscape, Pubmed, Youtube.com

15

16 Solution: Nevap Suction Line ET tube
Core Competencies Simple & Effective Unique Low Risk Integratable Manufacturable 16

17 Solution: Nevap Suction Line ET tube
Core Competencies Simple & Effective Unique Low Risk Integratable Manufacturable Class II Device, Predicate Devices needed only bench testing to gain FDA clearance.

18

19 Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts

20 Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist 20

21 Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist “If it can live up to its claims, this could help a lot of people,” -Jim Fink PhD Respiratory Industry Expert. 21

22 Testimonials & 3rd Party Validation
“It just makes sense to Anesthesiologists” -Lynn White MD Anesthesiologist/CEO Patient Shield Concepts “When will this be available for clinical testing? I’ll write up a proposal” -Arash Esmailzadegan MD Anesthesiologist “If it can live up to its claims, this could help a lot of people,” -Jim Fink PhD Respiratory Industry Expert. “This sounds very promising, when will we have more data in patients” -Mike Rosenthal MD Anesthesiologist/ Professor Emeritus 22

23 Competitive Devices

24 Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes 24

25 Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes Better Outcomes/Re-admissions Save Hospital $$$ Billions Decrease Legal Liability

26 Technology: Nevap Suction Line ET tube
Patent Pending Technology 25 claims No Suction Blockage Regardless of patient movement Reinforced Suction Sealing Safely change tubes Better Outcomes/Re-admissions Save Hospital $$$ Billions Decrease Legal Liability Lower rates of “Superbugs” Additional Device Applications 26

27

28 Competitive Landscape
Conservatively, estimate VAP reduction rates of 75% & US Hospital Savings of $9B/yr Covidien Kimberly Clark Teleflex Nevap Market Rank 1 2 3 - Device Cost $40 $43 Tbd Residual Secretions ++ ++++ Border Suctioning +++++ Suction Blockage Rate ++- Airway Sealing Mucosal harm +++

29 350K Patients X $40/tube X 3.5used = $50M
US VAP Market Opportunity 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr Target Segment

30 350K Patients X $40/tube X 3.5used = $50M
US VAP Market Opportunity 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr Target Segment Key Decision Makers Anesthesiologists/Critical Care Nursing/Respiratory Therapy Hospital Administration 30

31 350K Patients X $40/tube X 3.5used = $50M
US VAP Market Opportunity 350K Patients X $40/tube X 3.5used = $50M Nevap US TAM = $150M/yr Target Segment Key Decision Makers Key Benefits Anesthesiologists/Critical Care Nursing/Respiratory Therapy Hospital Administration Saves $Billions/ Better Outcomes Readily Integrated Increase Hospital Revenue 31

32 Value Proposition (6 day ICU Stay) Gold Standard (1 tubes used)
X $40= $40(purchase price) X $55= $55(Medicare reimbursement) Net Hospital Profit $15 VAP Risk Costs ($-5328) Incidence: 22.2/1000days X $40,000 average cost Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Nevap (2 tubes used) X $40= $80(purchase price) X $55= $110 (Medicare reimbursement) Net Hospital Profit $30 VAP Risk Costs ($-1200) Incidence: 5/1000days X $40,000 average cost Hospital Profits $ 30 Hospital Savings $ 4128 Nevap Profit $ 68 Nevap New CPT Coding (2 tubes used) X $60= $120(purchase price) X $80= $160(Medicare reimbursement) Net Hospital Profit $40 VAP Risk Costs ($-1200) Incidence: 5/1000days X $40,000 average cost Hospital Profits $ 40 Hospital Savings $ 4128 Nevap Profit $ 102 TAM is now Triple $1.3B/yr

33 Current Competition Profile
Physician Bills One procedure Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34

34 Nevap $40 Price Point Physician Bills One procedure
Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Physician Bills Two procedures Hospital Profits $ 30 Hospital Savings $ 4128 Nevap Profit $ 68

35 Nevap $60 Price Point US TAM is $150M, Global Tam $450M
Physician Bills One procedure Hospital Profits $ 15 Hospital Savings $ 0 Competition Profit $34 Physician Bills Two procedures Hospital Profits $ 40 Hospital Savings $ 4128 Nevap Profit $ 102 US TAM is $150M, Global Tam $450M

36

37 Strategic Manufacturing Partner
Low Capital Equipment Costs Rapid & Experienced OEM Expertise Existing Bioteq Distribution Rapid high precision scalability Licensing/Partnership for small market countries Est. COG: <$2.00 (package, shipped)

38 Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc)

39 Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows

40 Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows Target & Garner thought leader Endorsements

41 Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows Target & Garner thought leader Endorsements Apply for Unique CMS coding

42 Market Strategy: Promotion/Sales
Generate Independent Clinical Data through existing network of Academic physicians (UM, NYU, etc) Target Anesthesia & Critical Care Groups through Publication, Medical Conferences, and Trade Shows Target & Garner thought leader Endorsements Apply for Unique CMS coding Target large hospital chains & distributorship for private labeling/licensing

43 US Business Strategy (sell on 10 unit basis)
Beachhead sales Academic Researchers Promotional target price $10 / free Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

44 US Business Strategy (sell on 10 unit basis)
Beachhead sales Academic Researchers Promotional target price $10 / free Anesthesia Groups Promotional target price $40 Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

45 US Business Strategy (sell on 10 unit basis)
Beachhead sales Academic Researchers Promotional target price $10 / free Anesthesia Groups Promotional target price $40 Distributors Target price $60 Est. COG: $2.00 (package, shipped) Gross Margins Est: 85+%

46 Milestones

47 Financial Projections
Amounts in Millions Q2 Q3 Q4 Yr1 Yr2 Yr3 Yr4 Yr5 Sales 0.02 0.15 0.17 3.0 7.0 13.0 27.0 Gross Margins 0.015 0.14 0.155 2.65 6.3 11.7 24.3 Marketing Sales 0.01 0.03 0.3 0.6 1.0 2.0 QA/Mfg 0.05 0.1 Admin 0.06 0.4 0.5 0.7 0.8 Total Exp 0.08 1.25 1.85 2.95 EBITDA -0.02 -0.035 5.05 9.85 21.25 *Est. GM = 85+% Break Even Profitability

48 Ask Founders Funding to date: $60,000 Raised to date: $350,000
$1M/20% equity ($350,000), PCT Filing $ 100K Pilot Run $ 250K IDE Study/Process Validation/ Quality Systems, Design History File, ($170,000) Biocomp Testing $ 100K Stability Testing $ 50K CE Mark $ 20K CMS Application, Stage II SBIR Grant, ($40,000) 510K $ 40K Legal/Accounting $ 40K Salaries $ 250K Business Dev $ 150K Completed Milestones Prototype US Patent Team Assembled Consultants Identified Manufacturing Partner Founders Funding to date: $60,000 Raised to date: $350,000

49 Summary Nevap Suction Line Endotracheal Tube
-Help hundreds of thousands US patients/yr -Saves US hospitals $Billions/yr Functional Prototype, Patent Pending Enormous Societal & Financial Returns Key Team of Professionals Physicians embrace design Strong Incentives Benjamin R. Wang MD (408)

50

51 Questions?


Download ppt "Pitch Deck for The Big Bang Competition Round 2"

Similar presentations


Ads by Google